Travere Therapeutics Inc. (TVTX)
TVTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1438533/000143853326000014/0001438533-26-000014-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | TVTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001438533 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | CA |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $490.7M |
| Net income | -$25.5M |
| Operating income | -$62.8M |
| Net margin | -5.2% |
| Operating margin | -12.8% |
| Revenue growth | +110.5% |
| Cash | $93.0M |
| Total assets | $605.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 9.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-02 |
| Cash and burn | $123.5M cash; operating cash flow $44.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 95,992,155 (2026-10-28); 89,472,327 a year earlier; 75,145,831 three years earlier. | Cover page 2026-10-28 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-05-07 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Diego, California, United States | PCAOB Form AP 2026-03-03 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $102.5M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $224.6M | -$52.3M | $98.2M | $123.5M | No debt tags | $651.0M | 10-Q 2026-11-02 |
| Q2 2026 2026-06-30 | $169.6M | -$34.8M | $58.1M | $117.7M | No debt tags | $591.3M | 10-Q 2026-08-04 |
| Q1 2026 2026-03-31 | $127.2M | -$37.1M | -$40.4M | $78.4M | No debt tags | $536.2M | 10-Q 2026-05-04 |
| Q4 2025 2025-12-31 | $129.7M | $2.7M | $60.7M | $93.0M | $311.7M | $490.7M | 10-K 2026-02-19 |
| Q3 2025 2025-09-30 | $164.9M | $25.7M | $14.3M | $110.9M | $311.4M | $435.8M | 10-Q 2026-11-02 |
| Q2 2025 2025-06-30 | $114.4M | -$12.8M | $5.0M | $75.2M | $379.9M | $333.9M | 10-Q 2026-08-04 |
| Q1 2025 2025-03-31 | $81.7M | -$41.2M | -$42.2M | $61.9M | $379.4M | $273.5M | 10-Q 2026-05-04 |
| Q4 2024 2024-12-31 | $74.8M | -$60.3M | -$35.7M | $58.5M | $379.0M | $233.2M | 10-K 2026-02-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-07 |
| Latest annual report | 10-K | 2026-02-19 |
| Latest quarterly / interim | 10-Q | 2026-11-02 |
| Latest current report | 8-K | 2026-11-02 |
| Latest proxy | DEFA14A | 2026-04-06 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.1% |
| 1 month | -2.2% |
| 3 months | -17.5% |
| Year to date | +32.6% |
| 1 year | +49.5% |
| From 52-week high | -25.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| COGT | Cogent Biosciences Inc. | $27.44 | -3.92% | $4.8B |
| EWTX | Edgewise Therapeutics Inc. | $43.68 | -4.90% | $4.8B |
| IONS | Ionis Pharmaceuticals Inc. | $28.01 | -3.61% | $4.7B |
| DNTH | Dianthus Therapeutics Inc. | $89.55 | -2.46% | $5.0B |
| LQDA | Liquidia Corporation | $56.37 | -1.81% | $5.1B |
| PTCT | PTC Therapeutics Inc. | $60.97 | -3.97% | $5.1B |
| ERAS | Erasca Inc. | $15.11 | -3.51% | $5.3B |
| MANE | Veradermics Incorporated | $128.05 | -1.24% | $5.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier